{"filing":{"accession_number":"0001171843-26-005744","cik":"0001574232","ticker":"ADXN","company_name":"Addex Therapeutics Ltd.","form":"6-K","filing_date":"2026-08-26","report_date":"2026-08-26","primary_document":"f6k_082626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1574232/000117184326005744/f6k_082626.htm"},"events":[{"id":29591,"run_id":27101,"accession_number":"0001171843-26-005744","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Addex announced the sale of 437,869 ADSs (representing 52,544,280 shares) for USD 2.8 million through an At the Market (ATM) offering agreement with H.C. Wainwright \u0026 Co. This is an unregistered equity issuance that dilutes existing shareholders. The disclosure explicitly states the outstanding shares increased to 210,292,217 shares, confirming material dilution. ATM offerings are a classic signal of capital-raising pressure at small- and mid-cap issuers.","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-08-26","form":"6-K","submitted_at":null,"items":[{"id":31918,"accession_number":"0001171843-26-005744","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Addex announced the sale of 437,869 ADSs (representing 52,544,280 shares) for USD 2.8 million through an At the Market (ATM) offering agreement with H.C. Wainwright \u0026 Co. This is an unregistered equity issuance that dilutes existing shareholders. The disclosure explicitly states the outstanding shares increased to 210,292,217 shares, confirming material dilution. ATM offerings are a classic signal of capital-raising pressure at small- and mid-cap issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:08:58.676186+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31918,"accession_number":"0001171843-26-005744","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Addex announced the sale of 437,869 ADSs (representing 52,544,280 shares) for USD 2.8 million through an At the Market (ATM) offering agreement with H.C. Wainwright \u0026 Co. This is an unregistered equity issuance that dilutes existing shareholders. The disclosure explicitly states the outstanding shares increased to 210,292,217 shares, confirming material dilution. ATM offerings are a classic signal of capital-raising pressure at small- and mid-cap issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:08:58.676186+00:00","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-08-26"}]}